Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 18, 1998

View Archived Issues

Nycomed Amersham: six-month highlights

Xenova: six-month highlights

Techniclone submits phase II TNT protocol to FDA

Medarex signs new MAb development agreement

Ilex Oncology and Symphar to develop novel anticancer drug

Approvable letter issued by FDA for Genzyme's Thyrogen

Nexell submits data requested by FDA

Cangene files for German approval of next-generation WinRho product

York Medical's DiaCIM will be administered to cancer patients

Novel use for a known antidepressant: doxepin relieves pruritus in patients with eczema

Pharmacological characterization of new Astra agent for airways diseases presented at EFMC

Early 1999 launch dates anticipated for EchoGen in European markets

Astra describes SAR leading to antithrombotic agent with novel mechanism of action

Yale University studies suggest potential new therapeutic target for schizophrenia

SB-234551 characterized as potent, selective, nonpeptide ETA receptor antagonist

Selective and sensitive p38 MAP kinase inhibitor identified by SmithKline Beecham

Squalene synthase inhibitor-derived compound is potent inhibitor of protein farnesyltransferase

RPR-132703: a second-generation PDE4 inhibitor from Rhone-Roulenc Rorer

Stilbene analogue of pranlukast is a potent LTD4 antagonist with improved pharmacokinetics

Icos reviews pipeline of drugs in clinical development

New bladder-selective M3 antagonist from Yamanouchi for urinary urge incontinence

Search for 5-HT2C ligands at Organon leads to the full agonist Org-38457

Canadian approval for Viramune announced

Preliminary analysis indicates good efficacy and safety of resiniferatoxin in urge incontinence

Therion and Ludwig Institute to develop cancer immunotherapies based on ESO-1 gene

Introgen establishes European-based subsidiary

Treatment aimed at correcting underlying causes of CF enters phase II

Acquisition of GenQuest by Corixa completed